Optimal dilution of the CYP1A1 antibody should be determined by the researcher.\. Western blot: 0.1-0.5 μg/mL,IHC (Frozen): 0.5-1 μg/mL,IHC (Paraffin): 0.5-1 μg/mL,FACS: 1-3 μg/10^6 cells
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
Lagerung
-20 °C
Informationen zur Lagerung
After reconstitution, the CYP1A1 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.
Target
CYP1A1
(Cytochrome P450, Family 1, Subfamily A, Polypeptide 1 (CYP1A1))
AHH antikoerper, AHRR antikoerper, CP11 antikoerper, CYP1 antikoerper, P1-450 antikoerper, P450-C antikoerper, P450DX antikoerper, Cyp1a2 antikoerper, P450-1 antikoerper, cyp1a1 antikoerper, CYP1A1 antikoerper, CYPIA1 antikoerper, Cyp45c antikoerper, Cypc45c antikoerper, P-450MC antikoerper, wu:fb63b04 antikoerper, zfCYP1A antikoerper, zgc:109747 antikoerper, ahh antikoerper, ahrr antikoerper, cp11 antikoerper, cyp1 antikoerper, cyp1a antikoerper, p1-450 antikoerper, p450-c antikoerper, p450dx antikoerper, cytochrome P450 family 1 subfamily A member 1 antikoerper, cytochrome P450 1A1 antikoerper, cytochrome P450, family 1, subfamily a, polypeptide 1 antikoerper, cytochrome P450, family 1, subfamily A, polypeptide 1 antikoerper, cytochrome P450 family 1 subfamily D polypeptide 1 antikoerper, cytochrome P4501A1 antikoerper, polycyclic hydrocarbon-inducible cytochrome P450c antikoerper, cytochrome P450, family 1, subfamily A antikoerper, cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 antikoerper, cytochrome P450 family 1 subfamily A member 1 L homeolog antikoerper, CYP1A1 antikoerper, CpipJ_CPIJ010542 antikoerper, Cyp1a1 antikoerper, cyp1d1 antikoerper, LOC100328613 antikoerper, cyp1a antikoerper, LOC102129994 antikoerper, cyp1a1.L antikoerper
Hintergrund
CYP1A1 is involved in phase I xenobiotic and drug metabolism (one substrate of it is theophylline). It is inhibited by fluoroquinolones and macrolides and induced by aromatic hydrocarbons. CYP1A1 is also known as AHH (aryl hydrocarbon hydroxylase). It is involved in the metabolic activation of aromatic hydrocarbons (polycyclic aromatic hydrocarbons, PAH), for example, benzo(a)pyrene (BP), by transforming it to an epoxide. In this reaction, the oxidation of benzo[a]pyrene is catalysed by CYP1A1 to form BP-7,8-epoxide, which can be further oxidized by epoxide hydrolase (EH) to form BP-7,8-dihydrodiol. Finally CYP1A1 catalyses this intermediate to form BP-7,8-dihydrodiol-9,10-epoxide, which is the ultimate carcinogen. However, an in vivo experiment with gene-deficient mice has found that the hydroxylation of benzo(a)pyrene by CYP1A1 can have an overall protective effect on the DNA, rather than contributing to potentially carcinogenic DNA modifications. This effect is likely due to the fact that CYP1A1 is highly active in the intestinal mucosa, and thus inhibits infiltration of ingested benzo(a)pyrene carcinogen into the systemic circulation.